Form 8-K · Current report
Cencora 8-K, filed Aug 12, 2026
- Filed
- CIK
- 0001140859
- Accession no.
- 0001104659-26-094676
Summary
Cencora said that certain Walgreens volume serviced separately from the prime vendor agreement began moving outside the company on July 1, 2026, while the prime vendor agreement itself remains unchanged and represents the vast majority of its Walgreens business; the shift was contemplated in Cencora's August 5, 2026 commentary on fourth-quarter expectations for its U.S. Healthcare Solutions segment. Cencora reaffirmed its previously issued fiscal 2026 adjusted diluted EPS guidance of $17.75 to $17.95.
Key points
- Volume serviced by Cencora separately from the prime vendor agreement began moving outside the company on July 1, 2026.
- The prime vendor agreement with Walgreens remains unchanged and constitutes the vast majority of Cencora's business with Walgreens.
- Cencora reaffirmed its previously issued adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
From the filing
Item 7.01. Regulation FD Disclosure. Beginning July 1, 2026, certain Walgreens volume that was being serviced by Cencora, Inc. (the “Company” or “Cencora”) separate from the prime vendor agreement began moving outside the Company. The prime vendor agreement, which remains unchanged, constitutes the vast majority of the Company's business with Walgreens. This was fully contemplated in Cencora’s August 5, 2026 commentary on fourth quarter expectations for its U.S. Healthcare Solutions segment. Cencora is reaffirming its previously issued adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.